NASDAQ$ELVN
Enliven Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported first quarter financial results and provided a business update.
Enliven Therapeutics reported positive proof of concept data from the Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% by 12 weeks in response-evaluable patients. The company's cash, cash equivalents, and marketable securities totaled $320.5 million, which is expected to provide cash runway into late 2026.
- Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving a 44% cumulative MMR rate by 12 weeks in response-evaluable patients.
- Advanced trials of ELVN-002, including activating the first site to evaluate ELVN-002 in combination with trastuzumab in patients with HER2+ cancers.
- Entered into a securities purchase agreement for a private investment in public equity (PIPE) financing resulting in gross proceeds of $90 million, extending cash runway into late 2026.
- Cash, cash equivalents and marketable securities totaled $320.5 million as of March 31, 2024.
Headline financials
Revenue & EPS history
Enliven Therapeutics · Revenue · Quarterly
$0
Forward guidance
Enliven Therapeutics expects Phase 1b data in 2025, and Phase 1 monotherapy data, Phase 1a/b Herceptin combination data in HER2+ CRC, and initial Phase 1a combination data in HER2+ MBC are expected in 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-0.4%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+7.4%
Avg return
30 days after
48%
11 / 23 earnings
Positive
+17.6%
Q2 2020
Best reaction
-22.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +4.3% | +3.4% | +35.1% | |
| Q3 2025 | -0.3% | +11.3% | -16.9% | |
| Q2 2025 | -0.8% | -1.1% | -0.1% | |
| Q1 2025 | +0.4% | +19.7% | +29.3% | |
| Q4 2024 | -3.5% | -7.7% | -14.6% | |
| Q3 2024 | -8.3% | -8.4% | -14.8% | |
| Q1 2024 | -2.0% | -5.9% | -10.1% | |
| Q4 2023 | -2.4% | +43.0% | +71.8% | |
| Q3 2023 | -9.3% | -12.4% | -4.5% | |
| Q2 2023 | -2.0% | -8.0% | -7.1% | |
| Q1 2023 | -2.4% | -0.3% | +8.8% | |
| Q4 2022 | +2.1% | +4.5% | +2.6% | |
| Q3 2022 | +0.4% | -5.5% | -1.3% | |
| Q2 2022 | +2.5% | -1.7% | -3.4% | |
| Q1 2022 | -6.1% | -11.5% | -12.2% | |
| Q4 2021 | +11.1% | +22.2% | -27.8% | |
| Q3 2021 | +0.8% | -3.8% | -20.2% | |
| Q2 2021 | +0.3% | -18.0% | -14.5% | |
| Q1 2021 | +12.8% | +15.8% | +27.3% | |
| Q4 2020 | -22.5% | -19.5% | -31.7% | |
| Q3 2020 | -3.4% | +13.9% | +57.0% | |
| Q2 2020 | +17.6% | +19.8% | +8.1% | |
| Q1 2020 | +1.1% | +4.4% | +108.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro